Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1). We report ≥2-year follow-up data for avelu...

Descripción completa

Detalles Bibliográficos
Autores principales: Apolo, Andrea B, Ellerton, John A, Infante, Jeffrey R, Agrawal, Manish, Gordon, Michael S, Aljumaily, Raid, Gourdin, Theodore, Dirix, Luc, Lee, Keun-Wook, Taylor, Matthew H, Schöffski, Patrick, Wang, Ding, Ravaud, Alain, Manitz, Juliane, Pennock, Gregory, Ruisi, Mary, Gulley, James L, Patel, Manish R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549450/
https://www.ncbi.nlm.nih.gov/pubmed/33037118
http://dx.doi.org/10.1136/jitc-2020-001246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549450/
https://www.ncbi.nlm.nih.gov/pubmed/33037118
http://dx.doi.org/10.1136/jitc-2020-001246

Ejemplares similares